Key points from article :
A new study led by Professor Alexandra Smith at the University of York and published in Haematologica has found that people with multiple myeloma, an incurable blood cancer, are living almost twice as long as they did two decades ago. By analysing data from more than 3,700 patients in England diagnosed between 2005 and 2019, researchers discovered that median survival has increased from 2.4 years to 4.5 years, with particularly strong gains seen in patients over 80.
The improvement is credited to advances in treatment that are more effective and less toxic, allowing even older and more vulnerable patients to benefit. For those aged 80 and above, the number surviving at least five years has risen five-fold since 2005, a striking development given that this group has historically been excluded from many clinical trials. Researchers argue the findings demonstrate why inclusive trial design is so important.
Despite the progress, experts warn that survival rates for myeloma remain “devastatingly low.” About 6,200 new cases are diagnosed each year in the UK, and while treatment has improved, myeloma is still incurable. Campaigners stress the need for faster access to new therapies and for clinical trials to be open to people from all backgrounds, ensuring equity in research opportunities and treatment.
Leaders at Cancer Research UK and Blood Cancer UK say the findings highlight the life-changing power of sustained investment in research and NHS capacity. They are calling for the upcoming National Cancer Plan for England to prioritise clinical trials, expand access to cutting-edge therapies, and speed up delivery of new treatments to patients. For many with myeloma, every extra year represents invaluable time with loved ones—making further advances urgent.
